Recombinant human erythropoietin in amyotrophic lateral sclerosis: A pilot study of safety and feasibility

Journal of Clinical Neurology (Korea)

Volumn 10, Issue 4, 2014, Pages 342-347

  Kim, Hyun Young ^a   Moon, Chanil ^a   Kim, Kyung Suk ^b   Oh, Ki Wook ^a   Oh, Seong Il ^a   Kim, Juhan ^a   Kim, Seung Hyun ^a  

^a Hanyang University   (South Korea)

^b Division of Dg and Ai Business   (South Korea)

Author keywords

Amyotrophic lateral sclerosis; Erythropoietin; Pilot study

Indexed keywords

EID: 84908067104     PISSN: 17386586     EISSN: 20055013     Source Type: Journal    
DOI: 10.3988/jcn.2014.10.4.342     Document Type: Article

References (32)

1. Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001;2: 806-819.
2. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med 2001;344:1688-1700.
3. de Carvalho M, Costa J, Swash M. Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:202-212.
4. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994;330:585-591.
5. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyo-trophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyo-troph Lateral Scler Other Motor Neuron Disord 2003;4:191-206.
6. Assaraf MI, Diaz Z, Liberman A, Miller WH, Arvanitakis Z, Li Y, et al. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. J Neuropathol Exp Neurol 2007;66:389-398.
7. Maiese K, Chong ZZ, Hou J, Shang YC. New strategies for Alzheimer’s disease and cognitive impairment. Oxid Med Cell Longev 2009; 2:279-289.
8. Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neu-robehavioral outcome in a rat model of Parkinson’s disease. Neurosci-ence 2007;146:1245-1258.
9. Ehrenreich H, Fischer B, Norra C, Schellenberger F, Stender N, Stiefel M, et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007;130(Pt 10):2577-2588.
10. Akdemir Ozisik P, Oruckaptan H, Ozdemir Geyik P, Misirlioglu M, Sargon MF, Kilinc K, et al. Effect of erythropoietin on brain tissue after experimental head trauma in rats. Surg Neurol 2007;68:547-555; discussion 555.
11. Ehrenreich H, Hinze-Selch D, Stawicki S, Aust C, Knolle-Veentjer S, Wilms S, et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007;12:206-220.
12. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Neuroprotective agents in schizophrenia and affective disorders. Expert Opin Pharma-cother 2006;7:837-848.
13. Koh SH, Kim Y, Kim HY, Cho GW, Kim KS, Kim SH. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and infammation. Eur J Neurosci 2007;25:1923-1930.
14. Konishi Y, Chui DH, Hirose H, Kunishita T, Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 1993;609:29-35.
15. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, et al. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab Brain Dis 2004;19:195-206.
16. Janik P, Kwiecinski H, Sokolowska B, Niebroj-Dobosz I. Erythropoie-tin concentration in serum and cerebrospinal fuid of patients with amy-otrophic lateral sclerosis. J Neural Transm 2010;117:343-347.
17. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al. Erythropoietin therapy for acute stroke is both safe and benefcial. Mol Med 2002;8:495-505.
18. Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135-141.
19. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-299.
20. Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa. Clini-cal evolution of a pleiotropic cytokine. Arch Intern Med 2004;164:262-276.
21. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and throm-bopoiesis in humans. Blood 2000;95:2983-2989.
22. Maschio G. Erythropoietin and systemic hypertension. Nephrol Dial Transplant 1995;10 Suppl 2:74-79.
23. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003;59:538-548.
24. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinet-ics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998;64:412-423.
25. Katavetin P, Inagi R, Miyata T, Shao J, Sassa R, Adler S, et al. Erythro-poietin induces heme oxygenase-1 expression and attenuates oxida-tive stress. Biochem Biophys Res Commun 2007;359:928-934.
26. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, et al. Erythropoietin selectively attenuates cytokine production and infam-mation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 2003;198:971-975.
27. Chong ZZ, Kang JQ, Maiese K. Erythropoietin: cytoprotection in vascular and neuronal cells. Curr Drug Targets Cardiovasc Haematol Disord 2003;3:141-154.
28. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, Brines ML, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002;952:128-134.
29. Cho GW, Koh SH, Kim MH, Yoo AR, Noh M Y, Oh S, et al. The neu-roprotective effect of erythropoietin-transduced human mesenchymal stromal cells in an animal model of ischemic stroke. Brain Res 2010; 1353:1-13.
30. Genc S, Akhisaroglu M, Kuralay F, Genc K. Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahy-dropyridine-induced neurotoxicity in C57BL mice and stimulates mu-rine astroglial glutathione peroxidase production in vitro. Neurosci Lett 2002;321:73-76.
31. Grignaschi G, Zennaro E, Tortarolo M, Calvaresi N, Bendotti C. Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotroph Lateral Scler 2007;8:31-35.
32. Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, et al. Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability. Amy-otroph Lateral Scler 2009;10:410-415.